U.S. markets closed

Cidara Therapeutics, Inc. (CDTX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.1400-0.0400 (-1.83%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1800
Open2.2100
Bid2.1300 x 1800
Ask2.1800 x 1400
Day's Range2.0800 - 2.2200
52 Week Range1.8200 - 4.4500
Volume645,824
Avg. Volume1,052,006
Market Cap103.23M
Beta (5Y Monthly)1.41
PE Ratio (TTM)N/A
EPS (TTM)-1.8020
Earnings DateFeb 25, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Motley Fool

    Could Johnson & Johnson Be a Big Winner in the Flu Vaccine Market?

    Johnson & Johnson (NYSE: JNJ) hasn't been a major player in the vaccine market in the past, but that's changing. It's now seeking to develop a flu vaccine through a recent deal with small biotech Cidara Therapeutics (NASDAQ: CDTX). In this Motley Fool Live video recorded on April 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J could become a big winner in the flu vaccine market.

  • Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
    GlobeNewswire

    Cidara Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

    SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021. Presentation Information:Date:Wednesday, April 14, 2021Time:1:30 PM ETWebcast: A live audio webcast and replay of the presentation will be available in the Investors section on the company’s website at www.cidara.com. About Cidara TherapeuticsCidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company’s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara’s proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com. INVESTOR CONTACT:Brian RitchieLifeSci Advisors(212) 915-2578britchie@lifesciadvisors.com MEDIA CONTACT:Patrick BurseyLifeSci Communications(203) 430-9545pbursey@lifescicomms.com

  • Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies
    Zacks

    Cidara (CDTX) Inks Agreement With J&J for Influenza Therapies

    Cidara (CDTX) and J&J ink a collaboration agreement to develop influenza candidates with the potential to provide protection against all influenza strains.